PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15735035-6 2005 Radioiodination via an indirect method attenuated uptake of radioiodine in tissues that express the Na/I symporter without affecting the ability to image the tumor xenografts. Iodine-131 60-71 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 100-114 31010838-1 2019 PURPOSE: New strategies to restore sodium iodide symporter (NIS) expression and function in radioiodine therapy-refractive anaplastic thyroid cancers (ATCs) are urgently required. Iodine-131 92-103 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 60-63 32292510-2 2020 NIS is a theranostic protein that allows non-invasive monitoring of the in vivo biodistribution of functional NIS expression by radioiodine imaging as well as the therapeutic application of 131I. Iodine-131 128-139 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 0-3 32292510-2 2020 NIS is a theranostic protein that allows non-invasive monitoring of the in vivo biodistribution of functional NIS expression by radioiodine imaging as well as the therapeutic application of 131I. Iodine-131 128-139 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 110-113 11704812-1 2001 Radioiodine therapy, the most effective form of systemic radiotherapy available, is currently useful only for thyroid cancer because of thyroid-specific expression of the sodium iodide symporter (NIS). Iodine-131 0-11 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 171-194 30224540-1 2019 The sodium iodide symporter (SLC5A5/NIS) as theranostic gene would allow for non-invasive imaging of functional NIS expression and therapeutic radioiodine application. Iodine-131 143-154 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 4-27 30224540-1 2019 The sodium iodide symporter (SLC5A5/NIS) as theranostic gene would allow for non-invasive imaging of functional NIS expression and therapeutic radioiodine application. Iodine-131 143-154 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 29-35 30224540-10 2019 IMPLICATIONS: These data expand the prospect of MSC-mediated radioiodine imaging-guided therapy of pancreatic cancer using the sodium iodide symporter as a theranostic gene in a clinical setting. Iodine-131 61-72 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 127-150 21575476-0 2011 [Transfer of sodium iodide symporter gene into glioma cells by recombinant adenovirus and radioiodine therapy for the glioma cells in vitro and in nude mice]. Iodine-131 90-101 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 13-36 28380420-7 2017 Administration of 131I in LPEI-PEG-GE11/NIS-treated mice resulted in significantly reduced tumor growth compared to controls as determined by magnetic resonance imaging, though survival was not significantly prolonged. Iodine-131 18-22 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 40-43 27458162-0 2016 Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery. Iodine-131 17-21 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 101-124 21851208-0 2011 Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene. Iodine-131 29-40 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 105-128 17611400-0 2007 In vivo long-term imaging and radioiodine therapy by sodium-iodide symporter gene expression using a lentiviral system containing ubiquitin C promoter. Iodine-131 30-41 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 53-76 21204761-0 2010 Human sodium iodide symporter added to multidrug resistance 1 small hairpin RNA in a single gene construct enhances the therapeutic effects of radioiodine in a nude mouse model of multidrug resistant colon cancer. Iodine-131 143-154 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 6-29 19789324-0 2009 Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene. Iodine-131 9-20 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 97-120 19789324-1 2009 PURPOSE: We recently reported the significant therapeutic efficacy of radioiodine therapy in various tumor mouse models following transcriptionally targeted sodium iodide symporter (NIS) gene transfer. Iodine-131 70-81 solute carrier family 5 (sodium iodide symporter), member 5 Mus musculus 157-180